申请人:SMITHKLINE BEECHAM PLC
公开号:EP1114821A1
公开(公告)日:2001-07-11
Compounds selected from the group consisting of:
trans-6-Acetyl-4S-(3,5-difluorobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3R-ol,
trans-6-Acetyl-4S-(2,3,4-trifuorobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3R-ol,
trans-6-Acetyl-4S-(5-fluoro-2-methylbenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3R-ol, and
trans-7-Acetyl-4-(4-fluorobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol are useful in the treatment and/or prophylaxis of anxiety, mania, depression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable or preventable with anti-convulsive agents; such as epilepsy; Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease, schizophrenia and/or aggression.
选自以下组别的化合物
反式-6-乙酰基-4S-(3,5-二氟苯甲酰氨基)-3,4-二氢-2,2-二甲基-2H-1-苯并吡喃-3R-醇、
反式-6-乙酰基-4S-(2,3,4-三氟苯甲酰氨基)-3,4-二氢-2,2-二甲基-2H-1-苯并吡喃-3R-醇、
反式-6-乙酰基-4S-(5-氟-2-甲基苯甲酰氨基)-3,4-二氢-2,2-二甲基-2H-1-苯并吡喃-3R-醇,和
反式-7-乙酰基-4-(4-氟苯甲酰氨基)-3,4-二氢-2,2-二甲基-2H-1-苯并吡喃-3-醇可用于治疗和/或预防焦虑症、躁狂症、抑郁症、与蛛网膜下腔出血或神经休克有关的失调症、与可卡因、尼古丁、酒精和苯二氮卓等滥用药物戒断有关的影响,以及可使用抗惊厥剂治疗或预防的失调症;如癫痫、帕金森病、精神病、偏头痛、脑缺血、老年痴呆症、精神分裂症和/或攻击行为。